Intimal hyperplasia regression from 6 to 12 months after stenting

Kuroda, Nakabumi; Kobayashi, Yoshio; Nameki, Mizuo; Kuriyama, Nehiro; Kinoshita, Tadahiko; Okuno, Tatsusada; Yamamoto, Yutaka; Komiyama, Nobuyuki; Masuda, Yoshiaki

doi:10.1016/s0002-9149(02)02205-1

Cited by 37 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Therefore, even though late catch-up was observed following DES implantations, this neointimal progression in DES would be minimal and might not reach a clinical threshold. Although Resolute showed neointimal suppression maintained up to 9 months, it has not been fully investigated how long late catch-up might continue.…”

Section: Ivus Results Of Resolute Trialmentioning

confidence: 99%

Short- and Mid-Term Intravascular Ultrasound Analysis of the New Zotarolimus-Eluting Stent With Durable Polymer - Results From the RESOLUTE Trial -

Waseda

Ako

Yamasaki

et al. 2010

Circ J

View full text Add to dashboard Cite

Section: Ivus Results Of Resolute Trialmentioning

confidence: 99%

Short- and Mid-Term Intravascular Ultrasound Analysis of the New Zotarolimus-Eluting Stent With Durable Polymer - Results From the RESOLUTE Trial -

Waseda

Ako

Yamasaki

et al. 2010

Circ J

View full text Add to dashboard Cite

“…Over the same time interval, intravascular ultrasound showed a 13% increase in lumen volume and a 28% reduction in neointimal volume. 40 Thinning of the in-stent neointima (increased transparency) 3 years after stenting has been visualized by coronary angioscopy. 41 The present study provides pathological insights into these observations of neointimal regression; beyond 18 months, the stent neointima becomes less cellular (potentially via SMC apoptosis) and richer in type I collagen.…”

Section: Neointimal Regressionmentioning

confidence: 99%

Extracellular Matrix Changes in Stented Human Coronary Arteries

et al. 2004

View full text Add to dashboard Cite

Background-Restenosis after stenting occurs secondary to the accumulation of smooth muscle cells (SMCs) and extracellular matrix (ECM), with the ECM accounting for Ͼ50% of the neointimal volume. The composition of the in-stent ECM has not been well characterized in humans. Methods and Results-Postmortem human coronary arteries (nϭ45) containing stents underwent histological assessment of neointimal proteoglycans, hyaluronan, collagen (types I and III), SMCs, and CD44 (a cell surface receptor for hyaluronan). The mean duration of stent implantation was 18.7 months; stents in place Ն3 to Ͻ9 months (nϭ17) were assigned to group 1, stents Ն9 to Ͻ18 months old (nϭ19) to group 2, and stents Ն18 months old (nϭ9) to group 3. In groups 1 and 2, neointimal versican and hyaluronan staining was strongly positive, colocalized with ␣-actin-positive SMCs, and was greater in intensity compared with group 3. Conversely, decorin staining was greatest in group 3. The neointima of both group 1 and 2 stents was rich in type III collagen, with reduced staining in group 3. Type I collagen staining was weakest in group 1 stents, with progressively stronger staining in groups 2 and 3. SMC density and stent stenosis were significantly reduced in group 3 stents compared with groups 1 and 2. CD44 staining colocalized with macrophages and was associated with increased neointimal thickness. Conclusions-The ECM within human coronary stents resembles a wound that is not fully healed until 18 months after deployment, followed by neointimal retraction. ECM contraction may be a target for therapies aimed at stent restenosis prevention.

show abstract

“…12) Intimal hyperplasia is the primary mechanism of in-stent restenosis. 16) Meticulous follow-up may reveal patients with BMS restenosis before intimal hyperplasia becomes flow-limiting stenosis and causes ACS. Routine follow-up angiography after PCI is common practice in Japan.…”

mentioning

confidence: 99%

Bare Metal Stent Restenosis Is Benign Clinical Entity in Japanese Patients

et al. 2010

Self Cite

View full text Add to dashboard Cite

SummaryRecently, several studies have showed that bare metal stent (BMS) restenosis is not a benign clinical entity. However, clinical presentation of BMS restenosis in Japanese patients has not been fully evaluated. Follow-up coronary angiography after BMS implantation was performed in 473 patients with 523 lesions. Of these, BMS restenosis was observed in 167 lesions (31.9%). Clinical presentation of BMS restenosis was classified into 4 categories: 1) acute myocardial infarction, 2) unstable angina, 3) stable angina, and 4) no symptom. Acute myocardial infarction (0%) and unstable angina (3.8%) were infrequent clinical presentations in patients with BMS restenosis compared to stable angina (26.9%) and no symptom (69.2%). BMS restenosis may be a benign clinical entity in Japanese patients. (Int Heart J 2010; 51: 227-230)

show abstract

Intimal hyperplasia regression from 6 to 12 months after stenting

Cited by 37 publications

References 19 publications

Short- and Mid-Term Intravascular Ultrasound Analysis of the New Zotarolimus-Eluting Stent With Durable Polymer - Results From the RESOLUTE Trial -

Short- and Mid-Term Intravascular Ultrasound Analysis of the New Zotarolimus-Eluting Stent With Durable Polymer - Results From the RESOLUTE Trial -

Extracellular Matrix Changes in Stented Human Coronary Arteries

Bare Metal Stent Restenosis Is Benign Clinical Entity in Japanese Patients

Contact Info

Product

Resources

About